AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

AZN.UK

10,426

+0.71%↑

GSK

1,425.5

+0.11%↑

Indivior PLC

Затворен

826 -0.42

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

817

Максимум

832

Ключови измерители

By Trading Economics

Приходи

-19M

47M

Продажби

-33M

266M

P/E

Средно за сектора

330

54.533

EPS

0.41

Марж на печалбата

17.669

Служители

1,030

EBITDA

-30M

76M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+22.06% upside

Дивиденти

By Dow Jones

Следващи печалби

24.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

259M

1.1B

Предишно отваряне

826.42

Предишно затваряне

826

Indivior PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.05.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23.05.2025 г., 21:57 ч. UTC

Горещи акции

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23.05.2025 г., 21:15 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23.05.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23.05.2025 г., 20:56 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Salesforce Back in Deal Talks With Informatica -- WSJ

23.05.2025 г., 20:51 ч. UTC

Топ новини

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

23.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.05.2025 г., 20:41 ч. UTC

Топ новини

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23.05.2025 г., 20:28 ч. UTC

Топ новини

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23.05.2025 г., 20:06 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23.05.2025 г., 20:06 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23.05.2025 г., 19:50 ч. UTC

Топ новини

Trump's Tariffs: Where Things Stand -- 16th Update

23.05.2025 г., 19:28 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23.05.2025 г., 19:28 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23.05.2025 г., 19:27 ч. UTC

Придобивния, сливания и поглъщания

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23.05.2025 г., 19:20 ч. UTC

Пазарно говорене

Crude Futures Post Modest Weekly Losses -- Market Talk

23.05.2025 г., 19:18 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23.05.2025 г., 18:57 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23.05.2025 г., 18:54 ч. UTC

Топ новини

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23.05.2025 г., 18:53 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23.05.2025 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23.05.2025 г., 18:13 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

23.05.2025 г., 18:13 ч. UTC

Пазарно говорене

Gold Trades Higher on Reminder of Risk -- Market Talk

23.05.2025 г., 18:00 ч. UTC

Топ новини

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23.05.2025 г., 17:51 ч. UTC

Пазарно говорене
Печалби

Workday Sees Higher Bar for Guidance -- Market Talk

23.05.2025 г., 17:42 ч. UTC

Топ новини

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23.05.2025 г., 17:39 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23.05.2025 г., 17:07 ч. UTC

Топ новини

Trump's Tariffs: Where Things Stand -- 15th Update

23.05.2025 г., 17:04 ч. UTC

Пазарно говорене
Печалби

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Indivior PLC Прогноза

Ценова цел

By TipRanks

22.06% нагоре

12-месечна прогноза

Среден 1,014.32 GBX  22.06%

Висок 1,100 GBX

Нисък 967.968 GBX

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Indivior PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.